poisar

Stocks · News reference

Teva Pharmaceutical Industries Reports Q3 2026 Financial Results and Raises Full-Year Outlook

Teva reported third-quarter 2026 revenue of $4.395 billion and adjusted earnings per share of $0.86, exceeding analyst expectations, while raising its full-year 2026 revenue and earnings guidance.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

TEVA
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. James Halley

    Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?

    Teva Pharmaceuticals is executing a successful turnaround strategy, shifting from generics to higher-margin branded therapies. Its three key drugs (Austedo, Ajovy, Uzedy) grew sales 33% year-over-year to $1.1 billion in Q3, while gross margins improved to 55.5%. The company has paid down $12 billion in debt since 2019 and received investment-grade ratings. However, overall Q3 revenue declined 2% due to generic drug competition, and the company faces headwinds from commoditized generics. Despite recent gains, the stock trades at less than 21x forward earnings.

    TEVA
  6. Earnings Transcripts

    Teva Pharmaceutical Indus Q3 2026 Earnings Call Transcript

    Teva Pharmaceutical Indus (NYSE:TEVA) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by

    TEVA